New centers on therapeutics look at real-life drug use

Article

Since 2000, there have been several types of warnings about the drug Remicade (infliximab), a biological therapeutic product indicated for rheumatoid arthritis and Crohn's disease. Tuberculosis and other opportunistic infections have been reported in clinical research and elsewhere. The manufacturer has warned that patients should be given a TB skin test, and that treatment for any latent TB infection should be started before infliximab use.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.